The stocks of PFE will be announcing their next results of quarterly ratings on the 4th of May. Most of the analysts have already predicted that the company will be putting up an EPS of $0.83 for the quarter. The company has already set an FY 2021 EPS at $3.10 with the upper range fixed at $3.20.
The Quarterly Estimates Of PFE
PFE did announce their quarterly data on the 2nd of February. The biopharmaceutical company had an EPS of $0.42 for this quarter, which was less than the consensus estimate set at $0.42. The net margin of the company has been set at 17.85%, with a 24.88% return on its equity.
The revenue generated by the company during this period was $11.68 billion, which is more than the analyst expectation of $11.32 billion. Just the previous year, the EPS posted by the company is $0.55, which implies an increase of 11.8% from the previous year.
The stocks of PFE traded on Tuesday at $38.68. The year low of the company $31.61, with a year high of $43.08. The moving average price of the company over a period of 50 days is $36.47, with a moving average price over a period of 200 days set at $36.72. The market cap of the company is $215.74 billion, with a 24.95 PE ratio, and a 2.79 PEG ratio. The debt-to-equity ratio of the company over the period was 0.76, with a 1.13 quick ratio.
There have been quite a few research equities that have commented on the stocks of PFE. Berenberg Bank has already put up a rating of neutral with a price target of $38 in a 23rd March research report.